Table 4.

Hematocrit.

Author, year, (ref), study design	Intervention/comparator	Study population	Follow-up	Hematocrit
Defreyne 2018 (111), Prospective study	TU/TE/Gel	192 transgender males	1 year	TU: 40.9%→ 45.1% (levels above 0.50: 2.2%)TE: 41.0%→ 46.0% (levels above 0.50: 13.4%)Gel: 40.0%→ 46.5% (levels above 0.50: 9.9%)
Emi 2008 (80), Prospective study	TE/no treatment	63 untreated and 48 treated transgender males	-	Untreated: 38.8% Treated: 44.9%
Levcikova 2017 (110), Prospective study	TU/none	69 men with hypogonadism		Increase in hematocrit in 30%
McNicholas 2003 (45), Randomized, multidose, multicenter, active-controlled study	Gel/patch	208 men with hypogonadism 68 testim 50, 71 testim 100, 68 andropatch.	90 days	Higher dosage of gel showed higher hematocrit
Minnemann 2008 (67), Open-label, randomized, prospective clinical trial	TE/TU	40 men with hypogonadism	30 weeks	TE: 44,4%→ 47.8%TU 43.3%→ 46.8%
Wang 2004 (78), Long-term, open-label efficacy study	Gel/patch	163 men with hypogonadism	3 years	9% hematocrit >0.56
Zitzmann 2013 (53), International, multicenter, one-arm, prospective, observational study in 23 countries	TU/none	1438 men with hypogonadism	1 year	No cases of >0.52